Low Alpha-Fetoprotein Levels Are Associated with Improved Survival in Hepatocellular Carcinoma Patients with Portal Vein Thrombosis

Digestive Diseases and Sciences

Volumn 61, Issue 3, 2016, Pages 937-947

  Carr, Brian I ^a   Guerra, Vito ^b  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

^b NATIONAL INSTITUTE FOR DIGESTIVE DISEASES   (Italy)

Author keywords

AFP; DCP; Portal vein thrombosis; Survival

Indexed keywords

ALBUMIN; ALKALINE PHOSPHATASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CISPLATIN; DECARBOXYPROTHROMBIN; GAMMA GLUTAMYLTRANSFERASE; BIOLOGICAL MARKER; PROTEIN PRECURSOR; PROTHROMBIN; TUMOR MARKER;

ADULT; ADVANCED CANCER; ALBUMIN BLOOD LEVEL; ALKALINE PHOSPHATASE BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; CANCER PROGNOSIS; CANCER SURVIVAL; CHEMOEMBOLIZATION; COHORT ANALYSIS; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIVER CELL CARCINOMA; LIVER FUNCTION TEST; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PROTHROMBIN TIME; RETROSPECTIVE STUDY; SEX DIFFERENCE; TUMOR VOLUME; AGED; COMPLICATION; LIVER TUMOR; METABOLISM; MORTALITY; ODDS RATIO; PORTAL VEIN; PROGNOSIS; STATISTICAL MODEL; VEIN THROMBOSIS;

AGED; ALPHA-FETOPROTEINS; BIOMARKERS; BIOMARKERS, TUMOR; CARCINOMA, HEPATOCELLULAR; COHORT STUDIES; FEMALE; HUMANS; LIVER NEOPLASMS; LOGISTIC MODELS; MALE; MIDDLE AGED; ODDS RATIO; PORTAL VEIN; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; RETROSPECTIVE STUDIES; VENOUS THROMBOSIS;

EID: 84958876278     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-015-3922-3     Document Type: Article

References (28)

1. Schöniger-Hekele M, Müller C, Kutilek M, Oesterreicher C, et al. Hepatocellular carcinoma in Central Europe: prognostic features and survival. Gut. 2001;48:103–109.
2. Kinoshita A, Onoda H, Fushiya N, Koike K, et al. Staging systems for hepatocellular carcinoma: current status and future perspectives. World J Hepatol. 2015;7:406–424.
3. Carr BI, Pancoska P, Branch RA. Tumor and liver determinants of prognosis in unresectable hepatocellular carcinoma: a large case cohort study. Hepatol Int. 2009;4:396–405.
4. Pirisi M, Avellini C, Fabris C, Scott C, et al. Portal vein thrombosis in hepatocellular carcinoma: age and sex distribution in an autopsy study. J Cancer Res Clin Oncol. 1998;124:397–400.
5. Carr BI, Kanke F, Wise M, Satomura S. Clinical evaluation of lens culinaris agglutinin-reactive alpha-fetoprotein and des-gamma-carboxyprothrombin in histologically proven hepatocellular carcinoma in the United States. Dig Dis Sci. 2007;52:776–782.
6. Hagiwara S, Kudo M, Kawasaki T, Nagashima M, et al. Prognostic factors for portal venous invasion in patients with hepatocellular carcinoma. J Gastroenterol. 2006;41:1214–1219.
7. Gotoh M, Nakatani T, Masuda T, Mizuguchi Y, et al. Prediction of invasive activities in hepatocellular carcinomas with special reference to alpha-fetoprotein and des-gamma-carboxyprothrombin. Jpn J Clin Oncol. 2003;33:522–526.
8. Koike Y, Shiratori Y, Sato S, Obi S, et al. Des-gamma-carboxyprothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer. 2001;91:561–569.
9. Carr BI, Kondragunta V, Buch SC, Branch RA. Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma: a two-cohort study. Cancer. 2010;116:1305–1314.
10. Taylor CR. Computed tomography in the evaluation of the portal venous system. J Clin Gastroenterol. 1992;14:167–172.
11. Tublin ME, Dodd GD 3rd. Baron RL Benign and malignant portal vein thrombosis: differentiation by CT characteristics. AJR Am J Roentgenol. 1997;168:719–723.
12. Rossi S, Ghittoni G, Ravetta V, et al. Contrast-enhanced ultrasonography and spiral computed tomography in the detection and characterization of portal vein thrombosis complicating hepatocellular carcinoma. Eur Radiol. 2008;18:1749–1756.
13. Zeng ZC, Fan J, Tang ZY, Zhou J, et al. Prognostic factors for patients with hepatocellular carcinoma with macroscopic portal vein or inferior vena cava tumor thrombi receiving external-beam radiation therapy. Cancer Sci. 2008;99:2510–2517.
14. Yamamoto Y, Ikoma H, Morimura R, Shoda K, et al. Post-hepatectomy survival in advanced hepatocellular carcinoma with portal vein tumor thrombosis. World J Gastroenterol. 2015;21:246–253.
15. Le Treut YP, Hardwigsen J, Ananian P, Saïsse J, et al. Resection of hepatocellular carcinoma with tumor thrombus in the major vasculature. A European case-control series. J Gastrointest Surg. 2006;10:855–862.
16. Zeng ZC, Fan J, Tang ZY, Zhou J, et al. Prognostic factors for patients with hepatocellular carcinoma with macroscopic portal vein or inferior vena cava tumor thrombi receiving external-beam radiation therapy. Cancer Sci. 2008;99:2510–2517.
17. Cheong JY, Lee KM, Cho SW, Won JH, et al. Survival benefits of intra-arterial infusion chemotherapy in patients with advanced hepatocellular carcinoma with portal vein tumor thrombosis. Hepatol Res. 2005;32:127–133.
18. Kim JM, Kwon CH, Joh JW, Ko JS, et al. C-reactive protein may be a prognostic factor in hepatocellular carcinoma with malignant portal vein invasion. World J Surg Oncol. 2013;11:92.
19. Chok KS, Cheung TT, Chan SC, Poon RT, et al. Surgical outcomes in hepatocellular carcinoma patients with portal vein tumor thrombosis. World J Surg. 2014;38:490–496.
20. Ye JZ, Zhang YQ, Ye HH, Bai T, et al. Appropriate treatment strategies improve survival of hepatocellular carcinoma patients with portal vein tumor thrombus. World J Gastroenterol. 2014;20:17141–17147.
21. Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, et al. Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology. 2008;47:71–81.
22. Lau WY, Sangro B, Chen PJ, Cheng SQ, et al. Treatment for hepatocellular carcinoma with portal vein tumor thrombosis: the emerging role for radioembolization using yttrium-90. Oncology. 2013;84:311–318.
23. Kokabi N, Camacho JC, Xing M, El-Rayes BF et al. Open-label prospective study of the safety and efficacy of glass-based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis. Cancer. 2015. doi:10.1002/cncr.29275.
24. No authors. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology. 1998;28:751–5.
25. Carr BI, Guerra V, Giannini EG, Farinati F, et al. Association of abnormal plasma bilirubin with aggressive hepatocellular carcinoma phenotype. Semin Oncol. 2014;41:252–258.
26. Carr BI, Lin CY, Lu SN. Platelet-related phenotypic patterns in hepatocellular carcinoma patients. Semin Oncol. 2014;41:415–421.
27. Carr BI, Guerra V, Giannini EG, Farinati F, et al. Significance of platelet and AFP levels and liver function parameters for HCC size and survival. Int J Biol Markers. 2014;29:e215–e223.
28. Xu XS, Wan Y, Song SD, Chen W, et al. Model based on γ-glutamyltransferase and alkaline phosphatase for hepatocellular carcinoma prognosis. World J Gastroenterol. 2014;20:10944–10952.